How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursive’s $400 million outlay represents the bulk of the company’s fundraising to date.

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

A FOX News original, Gallagher joined FNC at the network’s launch in 1996 and has covered breaking news stories throughout the past 26 years. On Inauguration Day 2025, he contributed to the extensive ...

Researchers have demonstrated for the first time that AI-assisted code can silently rewrite the digital files produced by the forensic DNA machines used in crime labs — the same computerized scan ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...